Results 61 to 70 of about 30,927 (236)

Real-world experience of Ibrutinib therapy in relapsed chronic lymphocytic leukaemia: results of a single-centre retrospective analysis [PDF]

, 2019
Background: Ibrutinib is a Bruton’s tyrosine-kinase (BTK) inhibitor that is approved as a second-line treatment in chronic lymphocytic leukemia (CLL). While recent trials have demonstrated impressive results for ibrutinib, there remains a paucity of real-
Chevassut, Timothy, Johnston, Rosalynd, Nuttall, Elisabeth, Trounce, Ellie, Tung, Joanna   +4 more
core   +1 more source

Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B‐cell lymphoma cohort

British Journal of Haematology, EarlyView.
The international prognostic index (IPI)‐driven trial inclusion criteria may have contributed to the failure of some of the first‐line trials in large B‐cell lymphoma (LBCL). GLA and LYSA collaborated to improve prognostic stratification in LBCL by analyzing data from trial cohorts and proposed the smIPI.
Umut Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, Uğur Hatipoğlu, Meral Uluköylü Mengüç, Ebru Pekgüç, Taner Tan, Eda Nuhoğlu Kantarcı, Metban Mastanzade, Ali Durdu, Merve Apaydın Kayer, Murat Özbalak, Tuğrul Elverdi, Asu Fergün Yılmaz, Deniz Gören, Tayfur Toptaş, Turgay Ulaş, Özgür Mehtap, Mehmet Sinan Dal, Olga Meltem Akay, Muhlis Cem Ar, Güray Saydam, Fevzi Altuntaş, Elif Birtaş Ateşoğlu, Burhan Ferhanoğlu   +24 more
wiley   +1 more source

Ibrutinib-Associated Atrial Fibrillation

JACC: Clinical Electrophysiology, 2018
Ibrutinib, a novel and potent Bruton tyrosine kinase inhibitor, is an effective and well-tolerated treatment for a variety of B-cell lymphomas. However, its use is associated with an increased incidence of atrial fibrillation (AF), ranging from 4% to 16%. We reviewed the original clinical trials that led to the approval of ibrutinib, as well as several
David M. Venesy, Ana Barac, Tomas G. Neilan, Ghulam M. Chaudhry, Ajay K. Sharma, Sachin P. Shah, Salim S. Hayek, Sarju Ganatra, Syed S. Mahmood, Saurbha Dani, Anju Nohria, Richard D. Patten, John D. Groarke, David Martin   +13 more
openaire   +3 more sources

Acute kidney injury after chimeric antigen receptor T‐cell therapy is associated with inferior survival in patients with relapsed/refractory large B‐cell lymphoma

British Journal of Haematology, EarlyView.
Summary Baseline risk factors for acute kidney injury (AKI) during chimeric antigen receptor T‐cell (CAR‐T) therapy are not well described. Hence, we evaluated the incidence and risk factors associated with AKI among patients undergoing CAR‐T for relapsed/refractory large B‐cell lymphoma. Among 155 patients, 28 (18%) developed AKI with a median time‐to‐
John Sharp, Qiuhong Zhao, Timothy J. Voorhees, David A. Bond, Yazeed Sawalha, John Reneau, Audrey Sigmund, Walter Hanel, Lalit Sehgal, Lapo Alinari, Robert Baiocchi, Jonathan E. Brammer, Kami Maddocks, Beth Christian, Evandro Bezerra, Nathan Denlinger, Sumithira Vasu, Marcos De Lima, Jason Prosek, Narendranath Epperla   +19 more
wiley   +1 more source

Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population‐based study

British Journal of Haematology, EarlyView.
In a nationwide cohort study, 873 patients with mantle cell lymphoma (MCL) were followed for a median of 7 years. During follow‐up, 28 patients developed secondary central nervous system (CNS) lymphoma (SCNSL) with a 5‐year cumulative incidence of 2.8% (95% confidence interval [CI] 1.7–3.9).
Trine Trab, Torgerð Ranadóttir, Iman Chanchiri, Ahmed Ludvigsen Al‐Mashhadi, Emma Berggreen Dall, Stine Rasch, Mette Johansen, Laura Mors Haunstrup, Gabriella Cunsolo, Christian Bjørn Poulsen, Thomas Stauffer Larsen, Simon Husby, Peter Brown, Eliza A. Hawkes, Tarec C. El‐Galaly, Kirsten Grønbæk   +15 more
wiley   +1 more source

Is a Malleable Active Site Loop the Key to High Substrate Promiscuity? Hybrid, Biocatalytic Route to Structurally Diverse Taxoid Side Chains with Remarkable Dual Stereocontrol

Angewandte Chemie, Volume 137, Issue 36, September 1, 2025.
A highly stereoselective, dynamic reductive kinetic resolution (DYRKR) entry into myriad Taxotere‐like side chains with Clostridium acetobutylicum alcohol dehydrogenase (CaADH) enzyme is reported. Follow‐on cross couplings expand the structural diversity of the library (36 total examples).
Gaurav P. Kudalkar, Florian Leidner, Nivesh Kumar, Jared L. Hass, Peter Madzelan, Douglas R. Powell, Victor W. Day, Pierre Le Magueres, Joseph D. Ferrara, Lee M. Daniels, Akihito Yamano, Sho Ito, Wei Niu, Helmut Grubmüller, Mark A. Wilson, David B. Berkowitz   +15 more
wiley   +2 more sources

Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. [PDF]

, 2016
The clinical course of chronic lymphocytic leukaemia (CLL) is heterogeneous, and treatment options vary considerably. The Connect® CLL registry is a multicentre, prospective observational cohort study that provides a real-world perspective on the ...
Farber, Charles M, Flick, E Dawn, Flinn, Ian W, Flowers, Christopher R, Grinblatt, David L, Kay, Neil E, Kipps, Thomas J, Kiselev, Pavel, Kozloff, Mark F, Lamanna, Nicole, Mato, Anthony, Nabhan, Chadi, Sharman, Jeff P, Sullivan, Kristen, Swern, Arlene S, Weiss, Mark A   +15 more
core   +1 more source

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition [PDF]

, 2015
Resistance to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted sequencing, we dissect evolution of ibrutinib resistance in serial ...
Lander, Eric Steven
core   +1 more source

Towards a chemo‐free approach for follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The therapeutic landscape of follicular lymphoma (FL) is undergoing a transformative shift driven by the advent of novel chemo‐free strategies that challenge the traditional chemo‐oriented paradigms; this shift offers promising alternatives for both newly diagnosed and relapsed or refractory (RR) patients.
Stefano Luminari, Emiliano Barbieri, Maria Elena Nizzoli   +2 more
wiley   +1 more source

Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia

British Journal of Haematology, EarlyView.
Summary Ibrutinib is metabolized by cytochrome P450 3A (CYP3A) and poses challenges with drug interactions. We conducted a population‐based cohort study of Ontario residents aged ≥66 years who initiated ibrutinib for chronic lymphocytic leukaemia (CLL) to evaluate the frequency of potential drug interactions involving moderate/strong CYP3A inhibitors ...
Tuan Hoang, Matthew C. Cheung, David N. Juurlink, Kelvin K. W. Chan, Cindy Lau, Ning Liu, Husam Abdel‐Qadir, Anca Prica, Annette E. Hay, Abi Vijenthira, Lee Mozessohn   +10 more
wiley   +1 more source